<DOC>
	<DOC>NCT00543491</DOC>
	<brief_summary>This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).</brief_summary>
	<brief_title>MK0767 and Sulfonylurea Combination Study (0767-027)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 Diabetes with inadequate glycemic control On Sulfonylurea monotherapy Male or nonpregnant Females Age 21 to 78 years, inclusive On a stable dose of sulfonylurea for at least 2 weeks prior to Visit 2/Week6 History of Type 1 diabetes Patient is currently on insulin (monotherapy or in combination with oral agent), Rosiglitazone or pioglitazone or other PPARy agonists, Metformin agents Patients with history of or intolerance of PPARy agonists</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>